Early non-steady-state population pharmacokinetics of oral cyclosporine in renal transplant recipients

被引:6
作者
Baek, Hyunjeong [1 ]
Han, Seunghoon [2 ,3 ]
Yim, Dong-Seok [2 ,3 ]
Kim, Sung Joo [4 ]
Lee, Soo-Youn [5 ]
Jang, Hye Ryoun [6 ]
Lee, Jung Eun [6 ]
Kim, Dae Joong [6 ]
Kim, Yoon-Goo [6 ]
Oh, Ha Young [6 ]
Huh, Wooseong [6 ]
机构
[1] Kangwon Natl Univ, Sch Med, Dept Med, Chunchon, South Korea
[2] Catholic Univ Korea, Coll Med, Dept Pharmacol, Seoul, South Korea
[3] PIPET, Seoul, South Korea
[4] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Surg, Seoul 135710, South Korea
[5] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Lab Med & Genet, Seoul 135710, South Korea
[6] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med, Seoul 135710, South Korea
关键词
renal transplantation; multidrug resistance 1 (MDR1) gene; cytochrome P450; GENETIC-POLYMORPHISMS; CALCINEURIN INHIBITORS; CYP3A5; MDR1; KIDNEY; FORMULATION; TACROLIMUS; REJECTION;
D O I
10.2147/DDDT.S70595
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
This study aimed to evaluate the change in the pharmacokinetics (PK) of cyclosporine in the non-steady-state period in the first week after renal transplantation; the factors influencing this change, including genetic variability; and the time point concentration that correlated best with drug exposure. Data were obtained from 69 patients, and PK studies were conducted on postoperative days (PODs) 2, 3, and 7. Samples were taken pre-dose and at 1, 2, 3, 4, 6, 8, and 12 hours after drug administration. MDR1, CYP3A4, and CYP3A5 were genotyped. A population PK analysis and correlational analysis between the concentration at each time point and the area under the time-concentration curve were performed. A two-compartment model with first-order absorption was chosen. The rate and extent of drug absorption showed a significant increase on POD3, followed by a slight decrease on POD7. Until POD3, 8 hours post-dose was the single time point concentration that correlated best with drug exposure and 3 hours was the best time point on POD7. In both analyses, the MDR1 genotype showed potential as a factor influencing PK change. We conclude that oral administration of cyclosporine and dose adjustment based on a single concentration measurement might result in unexpected drug exposure during this early posttransplantation period.
引用
收藏
页码:2241 / 2249
页数:9
相关论文
共 20 条
[1]   CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation [J].
Anglicheau, D ;
Thervet, E ;
Etienne, I ;
De Ligny, BH ;
Le Meur, Y ;
Touchard, G ;
Büchler, M ;
Laurent-Puig, P ;
Tregouet, D ;
Beaune, P ;
Daly, A ;
Legendre, C ;
Marquet, P .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 75 (05) :422-433
[2]  
Azarpira N, 2006, Exp Clin Transplant, V4, P416
[3]   Pharmacokinetics of oral cyclosporine (Neoral) in heart transplant recipients during the immediate period after surgery [J].
Banner, NR ;
David, OJ ;
Leaver, N ;
Davis, J ;
Breen, J ;
Johnston, A ;
Yacoub, MH .
TRANSPLANT INTERNATIONAL, 2002, 15 (12) :649-654
[4]  
Bechstein WO, 2000, TRANSPL INT, V13, P313, DOI 10.1111/j.1432-2277.2000.tb01004.x
[5]   Adequate early cyclosporin exposure is critical to prevent renal allograft rejection: Patients monitored by absorption profiling [J].
Clase, CM ;
Mahalati, K ;
Kiberd, BA ;
Lawen, JG ;
West, KA ;
Fraser, AD ;
Belitsky, P .
AMERICAN JOURNAL OF TRANSPLANTATION, 2002, 2 (08) :789-795
[6]   Cyclosporin -: An updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (Neoral®)1 in organ transplantation [J].
Dunn, CJ ;
Wagstaff, AJ ;
Perry, CM ;
Plosker, GL ;
Goa, KL .
DRUGS, 2001, 61 (13) :1957-2016
[7]   MDR1 C3435T polymorphisms correlate with cyclosporine levels in de novo renal recipients [J].
Foote, C. J. ;
Greer, W. ;
Kiberd, B. A. ;
Fraser, A. ;
Lawen, J. ;
Nashan, B. ;
Belitsky, P. .
TRANSPLANTATION PROCEEDINGS, 2006, 38 (09) :2847-2849
[8]   The effect of CYP3A5 and MDR1 (ABCB1) polymorphisms on cyclosporine and tacrolimus dose requirements and trough blood levels in stable renal transplant patients [J].
Haufroid, V ;
Mourad, M ;
Van Kerckhove, V ;
Wawrzyniak, J ;
De Meyer, M ;
Eddour, DC ;
Malaise, J ;
Lison, D ;
Squifflet, JP ;
Wallemacq, P .
PHARMACOGENETICS, 2004, 14 (03) :147-154
[9]   Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus [J].
Hesselink, DA ;
van Schaik, RHN ;
van der Heiden, IP ;
van der Werf, M ;
Gregoor, PJHS ;
Lindemans, J ;
Weimar, W ;
van Gelder, T .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 74 (03) :245-254
[10]   Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic-polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes [J].
Hesselink, DA ;
van Gelder, T ;
van Schaik, RHN ;
Balk, AHMM ;
van der Heiden, IP ;
van Dam, T ;
van der Werf, M ;
Weimar, W ;
Mathot, RAA .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 2004, 76 (06) :545-556